Vanderbilt Kennedy Center

Medication Study for Adolescents with Fragile X and behavior problems

Last Updated: Wednesday, January 16, 2013

Principal Investigator: Jeremy M. Veenstra-VanderWeele, M.D.

Other researchers: Cassandra Newsom, PhD and Kevin Sanders, MD

Learn more about Research Family Partners

Description

Research has identified the protein MGLUR5 as a neurochemical target for reducing characteristic behavior problems in adults with Fragile X. This medication should block this protein from being used in the brain.

The purpose of this study is to assess the safety and usefulness of three doses in treating behavioral symptoms of Fragile X.

  • There will be 9 visits with our Fragile X expert clinicians and 9 phone calls over 20 weeks.
  • Visits may include behavioral and cognitive assessments, blood or urine samples, or physical and neurological exams at no cost to you.
  • For 16 weeks you will take a placebo (sugar pill) or the medication twice a day.

Read more about Fragile X research at Vanderbilt by clicking here.

Participant Criteria

Adolescents (12-17 years old) with Fragile X syndrome

Compensation

Compensation for time and travel.

Visit Requirements

Nine visits over 20 weeks - between 1 and 3 hours in length.

Brochure

Download Brochure

Contact Information

Sarah Marler
(615) 936-3288
sarah.marler@vanderbilt.edu

Want to Participate in this Study?

Enter your name and contact information and this study's coordinators will contact you if there are openings available.

 
 
(Optional)

Browse Categories

Jeremy M. Veenstra-VanderWeele, M.D. needs participants for these other studies.

Visit this investigator's people page to list all of their studies together.